Autologous Cell Therapy for Heart Disease Transformed with Point-of-Care Processing and 3D Imaging with Dr. Peter Altman BioCardia TRANSCRIPT

Empowered Patient Podcast

Content provided by Karen Jagoda. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Karen Jagoda or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

3d ago

PDF•Episode home

Dr. Peter Altman, President and CEO of BioCardia, is focused on treating ischemic heart failure and chronic myocardial ischemia using autologous cells from the patient's bone marrow. The company has developed a cost-effective model that utilizes a pre-procedure diagnostic to select the optimal patients for this point-of-care system, which processes their cells in a single procedure. A key technology is the Helix catheter system, which enables minimally invasive delivery of cells into the heart, aided by the Heart3D Fusion imaging platform that provides a 3D map for precise cell delivery.

Peter explains, "BioCardia's focus is on ischemic etiology of heart disease. This is heart disease that results from poor perfusion, typically following, for example, a heart attack, which is an ischemic disease. And the two diseases we're working on are ischemic heart failure, which is often characterized by a large dilated heart. And in the second is chronic myocardial ischemia, which is characterized by what's called refractory angina or chest pain that actually can be incredibly severe. And so are our focus areas. And we're advancing cell therapies that have been shown to inherently improve the cells we're looking at, which are cells from the bone marrow space, the mononuclear cells that contain the CD34 and CD133 cell populations. They're actually involved in forming new microvasculature and supply."

"What we've done is come at it from a different perspective. Instead of selecting the cells and then manufacturing in a remote facility, we have a pre-procedure diagnostic that enables us to select the patients who have appropriate cells and then process them with a point-of-care cell processing platform, which involves just a simple disposable cartridge. And then we can treat these patients in a standard interventional cardiology setting at relatively low cost compared to all cell therapies."

#BioCardia #HeartDisease #AutologousCellTherapy #CellTherapy #3DImaging #Heart3DFusion #CardiAMP

biocardia.com

Listen to the podcast here

371 episodes

#Medicine #Science #Clinicaltrials #Digitalhealth #Healthcare #Medicalapps #Medicalresearch #Translationalmedicine #Fitness #Karen Jagoda #Doctor Who #Hospitality #MHealth #Nursing #Patient #Pharmacist